Sarepta Therapeutics reported second-quarter 2025 revenue of $611.1 million, a 42% jump from a year earlier, driven by $513.1 million in product sales. The company posted GAAP net income of $196.9 million, or $1.89 a diluted share, reversing a small loss in the comparable period of 2024 and generating positive operating and free cash flow. Cash, cash equivalents and investments rose to about $850 million at quarter-end. Growth was powered by Elevidys, Sarepta’s gene therapy for Duchenne muscular dystrophy. The U.S. Food and Drug Administration on 28 July cleared the firm to resume Elevidys shipments for ambulatory patients after reviewing safety data, ending a voluntary pause imposed earlier in July. Discussions continue with the agency on additional labeling and risk-mitigation steps before supply can restart for non-ambulatory patients. Management said a July restructuring is on track to deliver more than $100 million in savings by the end of 2025 and about $400 million annually from 2026, supporting repayment of 2027 convertible notes. Sarepta also highlighted several clinical milestones expected over the next 18 months for its siRNA portfolio targeting facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1, spinocerebellar ataxia type 2 and Huntington’s disease.